Oregon DUR Newsletter
These are newsletters released under the auspices of the historical Oregon Drug Use Review Board, which ceased to exist in 2013 and was subsequently replaced with the Oregon Pharmacy & Therapeutics Committee.
Volume 13 - 2011 | ||
| Issue | Table of Contents | |
| No. 3, September 2011 | Evidence Overview and Clinical Role of Dabigatran (Pradaxa) | |
| No. 2, May 2011 | Treatment of Insomnia | |
| No. 1, February 2011 | An Update in Therapeutic Options for Diabetes | |
Volume 12 - 2010 | ||
| Issue | Table of Contents | |
| No. 6, August 2010 | Lipid Profile Screening in Second-Generation Antipsychotic Users: The Gap Between Policy and Practice - Please note this correction for the above: Issue 6 Errata | |
| No. 5, July 2010 | Combination Long-Acting Beta-Agonist and Inhaled Corticosteroid Therapy for Asthma: New Safety Concerns - References for Above | |
| No. 4, May 2010 | Truth or Fiction: PPIs Inhibit Clopidogrel Effectiveness? | |
| No. 3, April 2010 | Answers to Frequently Asked Questions About Atypical Antipsychotics | |
| No. 2, February 2010 | Strategies to Manage Pain in Patients At Risk for Substance Abuse | |
| No. 1, January 2010 | The Oregon Health Plan Preferred Drug List: What is it, What's on it and Why? | |
Volume 11 - 2009 | ||
| Issue | Table of Contents | |
| No. 6, November 2009 | Oregon Alliance Working for Antibiotic Resistance Education (AWARE) | |
| No. 5, October 2009 | Resources for Management of 2009 H1N1 Influenza | |
| No. 4, September 2009 | Treatment Resistant Depression - Going Beyond Traditional Antidepressant Therapy | |
| No. 3, August 2009 | Summary of 2009 Drug Effectiveness Review Project (DERP) Report of Proton Pump Inhibitors (PPIs) | |
| No. 2, June 2009 | An Overview of the Safety of Methadone Use and Recommendations for Judicious Use | |
| No. 1, April 2009 | The Evidence for Psychotropic Medication Management in Children and Adolescents | |
Volume 10 - 2008 | ||
| Issue | Table of Contents | |
| No. 9, December 2008 | Generic Antiepileptic Substitution | |
| No. 8, November 2008 | Transdermal Patches: To Cut or Not Cut | |
| No. 7, October 2008 | Antibiotic Resistance Education | |
| No. 6, September 2008 | Neuropathic Pain Treatment | |
| No. 5, August 2008 | Antidepressant Treatment Selection and Treatment Resistant Depression | |
| No. 4, July 2008 | New FDA Law Stimulates Availability of Drug Safety Information | |
| No. 3, May 2008 | The Challenges of Heart Failure Management | |
| No. 2, April 2008 | Smoking Cessation - Oregon's Free Tobacco Quit Line | |
| No. 1, March 2008 | Cough and Cold Products | |
Volume 9 - 2007 | ||
| Issue | Table of Contents | |
| No. 3, December 2007 | An Intervention to Reduce Overuse of Acetaminophen in an Oregon Medicaid Population | |
| No. 2, March 2007 | Updates in Psychopharmacology: New Indications for Risperidone and Bupropion | |
| No. 1, February 2007 | Recognizing and Addressing Conflict of Interest | |
Volume 8 - 2006 | ||
| Issue | Table of Contents | |
| No. 6, December 2006 | Varenicline: What is its role for smoking cessation? | |
| No. 5, September 2006 | Updates in Psychopharmacology: Two New Patches | |
| No. 4, August 2006 | b-Agonist Warnings: What Do They Mean for Asthma Treatment? | |
| No. 3, April 2006 | Updates in Psychopharmacology | |
| No. 2, March 2006 | Selecting Antihypertensive Therapy | |
| No. 1, February 2006 | New Medications for the Treatment of Insomnia | |
Volume 7 - 2005 | ||
| Issue | Table of Contents | |
| No. 8, December 2005 | Antiviral Drugs for Treatment and Prophylaxis of Influenza | |
| No. 7, November 2005 | The FDA Advises Clinicians About Fentanyl Caused Deaths | |
| No. 6, September 2005 | Questions About Cutting Tablets to Cut Costs | |
| No. 5, August 2005 | Pharmacotherapy of Neuropathic Pain – The Evidence | |
| No. 4, June 2005 | New Medical Research Round Up | |
| No. 3, April 2005 | Generic Substitution Issues for Warfarin and Levothyroxine | |
| No. 2, February 2005 | An Update on the Partnership for Psychiatric Medication Access Project | |
| No. 1, January 2005 | Drugs for Chronic Obstructive Pulmonary Disease | |
Volume 6 - 2004 | ||
| Issue | Table of Contents | |
| No. 8, Sept. 2004 | Off-Label Use of Modafinil (Provigil®) | |
| No. 7, August 2004 | Three New Classes Added to OHP Drug List | |
| No. 6, July 2004 | Hepatitis C: Recommendations for Antiviral Therapy | |
| No. 5, June 2004 | Atypical Antipsychotics and Metabolic Abnormalities | |
| No. 4, April 2004 | Two New Drug Review Programs Set to Start in May | |
| No. 3, March 2004 | Use of Selective Serotonin Reuptake inhibitors in Pediatric Patients | |
| No. 2, February 2004 | Prilosec OTC Offers Exceptional Value for PPI Therapy | |
| No. 1, January 2004 | Oregon Alliance Working for Antibiotic Resistance Education (AWARE) | |
Volume 5 - 2003 | ||
| Issue | Table of Contents | |
| No. 9, December 2003 | Nonpharmacologic and Pharmacologic Interventions in Alzheimer's Disease | |
| No. 8, October 2003 | FluMist: New Flu Option Not Recommended For High Risk Patients | |
| No. 7, September 2003 | The OHP Preferred Drug List: What is it, what's on it and why? | |
| No. 6, August 2003 | Recognizing Medication Overuse Headache | |
| No. 5, May 2003 | - Methadone Dosing and Conversion: Be Conservative - Two New Mental Health Drug Options Reviewed: Aripiprazole (Abilify) and Atomoxetine (Straterra) | |
| No. 4, April2003 | New Use Criteria for Dronabinol and 5-HT3 Receptor Antagonists | |
| No. 3, March2003 | Options for Patients Without Prescription Drug Coverage | |
| No. 2, Feb.2003 | Ezetimibe: A Novel Selective Cholesterol Absorption Inhibitor | |
| No. 1 Jan. 2003 | - Generic Psychotropic Drugs Offer Quality and Affordability - Dispelling Marketing Myths | |
Volume 4 - 2002 | ||
| Issue | Table of Contents | |
| No. 10, Dec. 2002 | - Combination Hormonal Contraception Options Reviewed - Lunelle RecallCombination Hormonal Contraception Options Reviewed | |
| No. 9, Nov. 2002 | The Role of Advair for Treatment of Asthma and COPD | |
| No. 8, Oct. 2002 | Carisoprodol (Soma) and Sedative Quantities to be Restricted on November 15, 2002 | |
| No. 7, Sept. 2002 | Zelnorm®: What is the evidence of benefit for IBS? | |
| No. 6, August 2002 | Fluoroquinolones in Outpatient Infections: Friend or Foe? | |
| No. 5, July 2002 | Pharmacotherapy for Overactive Bladder: Oxybutynin vs. Tolterodine | |
| No. 4, June 2002 | HRC Reports Evidence in First Classes for OHP Drug Plan | |
| No. 3, May 2002 | - Long-Acting Opioids: A Second Glance - Depakote ER® for Depakote® Errors Noted | |
| No. 2, April 2002 | A Review of Stimulant Medications | |
| No. 1, March 2002 | - Lipid Treatment News - The OHP Practitioner-Managed Prescription Drug Plan | |
Oregon State University grants permission to use this newsletter for noncommercial educational and research purposes only. The copyright and this grant of permission do not allow the use of the name of Oregon State University to be used in any advertising or publicity pertaining to the use of this newsletter without specific written prior authorization from the OSU College of Pharmacy.